Chimeric Antigen Receptor News and Research

RSS

CAR macrophages can be used to effectively fight solid tumors

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors.

23 Mar 2020

Investigational CAR-T therapy for Hodgkin lymphoma receives fast-track designation from FDA

Based on proof-of-concept results from clinical trials at University of North Carolina Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.

9 Mar 2020

UCI makes tremendous strides in prevention, early detection and treatment of cancer

Like most people, John Gifford wasn't looking forward to a colonoscopy when he arrived on the UCI Medical Center campus in Orange in 2018.

23 Feb 2020

Bioengineers create light-controllable CAR T cells for cancer immunotherapy

Bioengineers at the University of California San Diego have developed a control system that could make CAR T-cell therapy safer and more powerful when treating cancer.

19 Feb 2020

Universal 'One-Size-Fits-All' Cancer Treatment

Andrew Sewell speaks to News-Medical about his breakthrough research, in which he has discovered a new T-Cell that could treat most cancers.

14 Feb 2020

Research reveals novel way to treat cancers using CAR T cell therapy

Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at Huntsman Cancer Institute at the University of Utah to try to improve the depth and durability of treatment response in multiple myeloma through a new cancer cell targeting mechanism.

10 Feb 2020

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.

6 Feb 2020

Researchers develop an emergency stop switch for CAR T-cell therapies

Immunotherapy, unlike chemotherapy and radiotherapy, arms the body's immune system to attack cancer cells. In recent years, it has proven to be remarkably successful at treating leukemia, lymphoma and other liquid cancers, or cancers present in body fluids.

4 Feb 2020

Ludwig Cancer Research study develops a safer CAR-T therapy

A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell-;a family of promising immunotherapies for cancer- that can be switched on and off on demand.

3 Feb 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.

3 Feb 2020

New discovery could enable scientists to fine-tune activity of cancer-killing immune cells

A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects.

31 Jan 2020

Lab tests reveal that newly discovered T-cell can kill various types of cancer

Scientists have discovered a T-cell receptor that has proven effective in targeting a variety of cancers in mice and in human cells within the lab.

21 Jan 2020

Lab-grown brain organoids may hold the answers to personalized treatments for glioblastomas

Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it.

26 Dec 2019

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

16 Dec 2019

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

9 Dec 2019

Small, thin metal mesh loaded with T cells shrinks tumors in ovarian cancer models

New findings published Dec. 9 in Nature Biomedical Engineering from scientists at Fred Hutchinson Cancer Research Center show for the first time that a piece of small, thin metal mesh loaded with cancer-fighting immune cells shrinks tumors in preclinical models of ovarian cancer.

9 Dec 2019

New approach can improve the activity of CAR-T cells against blood and solid cancers

A new approach to programing cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiveness against human cancer cells grown in the laboratory and in mice, according to a study by researchers at the Stanford University School of Medicine.

5 Dec 2019

New textbook on mysterious and deadly cytokine storm syndrome

There's no telling where the call will come from, or when. But Randy Cron, M.D., Ph.D., professor of pediatrics and medicine at UAB, knows to expect them.

11 Nov 2019

MD Anderson and Takeda announce agreement to develop off-the-shelf CAR NK-cell therapy platform

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, for the treatment of B-cell malignancies and other cancers.

5 Nov 2019